Atrial fibrillation (stroke prevention) - rivaroxaban: review decision April 2013 information
History
Documents created during the development process.
Background information
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Appendix A - decision paper presented to the Institute's Guidance Executive
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: review proposal - February 2013 information
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 632 KB)
Atrial fibrillation (stroke prevention) - rivaroxaban: equality impact assessment - guidance development
-
Atrial fibrillation (stroke prevention) - rivaroxaban: equality impact assessment - guidance development
-
Atrial fibrillation (stroke prevention) - rivaroxaban: final appraisal determination
-
Atrial fibrillation (stroke prevention) - rivaroxaban: final appraisal determination information
-
Atrial fibrillation (stroke prevention) - rivaroxaban: final appraisal determination document
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: consultee and commentator comments on the ACD
-
Atrial fibrillation (stroke prevention) - rivaroxaban: AntiCoagulation Europe
-
Atrial fibrillation (stroke prevention) - rivaroxaban: AntiCoagulation Europe (PDF 51 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Arrhythmia Alliance
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Arrhythmia Alliance (PDF 373 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Atrial Fibrillation Association
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Atrial Fibrillation Association (PDF 682 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Bayer
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Bayer (PDF 610 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Boehringer Ingelheim
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Boehringer Ingelheim (PDF 596 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Bristol Myers-Squibb and Pfizer
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Bristol Myers-Squibb and Pfizer (PDF 174 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: British Association of Stroke Physicians
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Commissioning Support Appraisal Service
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Department of Health
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Department of Health (PDF 4.6 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Medicines and Healthcare Products Regulatory Agency
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: National Clinical Guidelines Centre
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: NHS Berkshire cluster
-
Atrial fibrillation (stroke prevention) - rivaroxaban: NHS Berkshire cluster (PDF 5.5 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Nursing
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Nursing (PDF 59 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Pathologists and BSH
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: The British Cardiovascular Intervention Society
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: The Stroke Association
-
Atrial fibrillation (stroke prevention) - rivaroxaban: The Stroke Association (PDF 38 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: expert comments on the ACD
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Potter
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Potter (PDF 25 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Sayers
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Sayers (PDF 97 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: comments on the ACD received from the public through the NICE website
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: ERG's response to Bayer's comments on the ACD
-
Atrial fibrillation (stroke prevention) - rivaroxaban: ERG response
-
Atrial fibrillation (stroke prevention) - rivaroxaban: ERG response (PDF 468 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: additional report
-
Atrial fibrillation (stroke prevention) - rivaroxaban: additional report (PDF 170 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: second additional report
-
Atrial fibrillation (stroke prevention) - rivaroxaban: second additional report (PDF 269 KB)
Atrial fibrillation (stroke prevention) - rivaroxaban: appraisal consultation
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appraisal consultation
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appraisal consultation document information
-
Atrial fibrillation (stroke prevention) - rivaroxaban: evaluation report
-
Atrial fibrillation (stroke prevention) - rivaroxaban: pre-meeting briefing
-
Atrial fibrillation (stroke prevention) - rivaroxaban: pre-meeting briefing (PDF 344 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Evidence Review Group report
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Evidence Review Group report
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Evidence Review Group report (PDF 2.2 MB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: ERG report erratum
-
Atrial fibrillation (stroke prevention) - rivaroxaban: ERG report erratum (PDF 437 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Evidence Review Group report - factual accuracy check
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Bayer
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Bayer (PDF 2.17 MB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: clarification
-
Atrial fibrillation (stroke prevention) - rivaroxaban: NICE clarification letter
-
Atrial fibrillation (stroke prevention) - rivaroxaban: NICE clarification letter (PDF 471 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: manufacturer response to the NICE clarification letter
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: eligibility criteria
-
Atrial fibrillation (stroke prevention) - rivaroxaban: eligibility criteria (PDF 193 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: patient group, professional group and NHS organisation submission statements
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Arrhythmia Alliance
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Arrhythmia Alliance (PDF 85 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Atrial Fibrillation Association (AFA Affiliated)
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Heart Rhythm UK
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Heart Rhythm UK (PDF 84 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: NHS Berkshire
-
Atrial fibrillation (stroke prevention) - rivaroxaban: NHS Berkshire (PDF 70 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Nursing
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Nursing (PDF 4.9 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Royal College of Pathologists and BSH
-
-
Atrial fibrillation (stroke prevention) - rivaroxaban: expert written personal statements
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Eaton
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Eaton (PDF 98 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Jerrome
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Jerrome (PDF 93 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Maclean
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Maclean (PDF 96 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Potter
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Potter (PDF 144 KB)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Sayers
-
Atrial fibrillation (stroke prevention) - rivaroxaban: Sayers (PDF 129 KB)
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix A - final matrix
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix A - final matrix
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix A - final matrix (PDF 59 KB)
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix B - final scope
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix B - final scope
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix B - final scope (PDF 38 KB)
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix C - response to consultee and commentator comments on the draft remit and draft scope (pre-referral)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix C - response to consultee and commentator comments on the draft remit and draft scope (pre-referral)
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix D - response to consultee and commentator comments on the provisional matrix of consultees and commentators
-
Atrial fibrillation (stroke prevention) - rivaroxaban: appendix D - response to consultee and commentator comments on the provisional matrix of consultees and commentators
-
Atrial fibrillation (stroke prevention) - rivaroxaban: draft scope for consultation (pre-referral) - July 2010
-
Atrial fibrillation (stroke prevention) - rivaroxaban: draft scope for consultation (pre-referral) - July 2010
-
Atrial fibrillation (stroke prevention) - rivaroxaban; provisional matrix (pre-referral) - July 2010
-
Atrial fibrillation (stroke prevention) - rivaroxaban; provisional matrix (pre-referral) - July 2010
-